120,000-liter biopharmaceutical production facility to begin commercial output next year
Company secures first large-scale CMO contract with global pharma firm a day before opening
Lotte Group Chairman Shin Dong-bin calls plant 'turning point' for Korea's biotech competitiveness
Lotte Biologics held a completion ceremony Wednesday for Plant 1 at its Songdo Bio Campus in Incheon, formally launching its domestic production hub. With large-scale manufacturing infrastructure in place and an initial commercial order already secured, the company's biotech business — a key growth engine for Lotte Group — has made its full entry into the global contract development and manufacturing organization market.
The ceremony took place at the Songdo Bio Campus on Wednesday.
About 300 guests attended, including Lotte Group Chairman Shin Dong-bin, Lotte Biologics co-CEOs James Park and Shin Yu-yeol, Incheon Mayor Park Chan-dae, Assembly members Song Young-gil of Incheon's Yeonsu-gu (Gap) district, Jeong Il-yeong of Yeonsu-gu (Eul) and Bae Jun-yeong of Jung-gu, Ganghwa-gun and Ongjin-gun, Vice Minister of Trade, Industry and Energy Park Dong-il, Yeonsu-gu District Mayor Lee Jae-ho, and Ministry of Health and Welfare Director General of Health and Medical Policy Jeong Gyeong-sil. Prime Minister Han Seong-sook delivered congratulatory remarks via video.
The ceremony opened with a commemorative video screening and the national salute, followed by welcome addresses, a company introduction video and congratulatory video presentations. Guests then heard speeches from key attendees before a ribbon-cutting ceremony, after which they toured the main facilities of Plant 1.
In his address, Lotte Group Chairman Shin called the biotech business "a future growth engine for Lotte Group and a next-generation industry that will lead the Republic of Korea forward." He said he hopes Plant 1 at the Songdo Bio Campus "will become an important turning point that elevates the competitiveness of Korea's biotech industry beyond the growth of Lotte Group."
Shin added that the company would "create quality jobs centered on Songdo and nurture outstanding biotech talent, while working closely with the government, relevant agencies, customers and partners to contribute to the development of Korea's biotech industry and strengthen national competitiveness."
Co-CEO James Park said Plant 1 achieved GMP-ready status six months ahead of the original schedule. "This is an achievement born of the dedication of all our employees, and it will serve as a solid foundation for taking another leap forward in the global market," he said.
Co-CEO Shin Yu-yeol said the completion of the Songdo Bio Campus "is meaningful in that it goes beyond the completion of a new production facility — it lays the groundwork for Lotte Biologics to contribute to enhancing Korea's large-scale biopharmaceutical manufacturing capabilities." He said the company aims to become "a CDMO partner that walks alongside customers from a long-term perspective, grounded in quality, technology and trust that customers can feel," under the vision of being "the new benchmark for next-generation CDMOs."
Prime Minister Han said in a video address that Plant 1 "is the first fruit of Lotte Group's bold investment in the biotech industry with an eye to the future, and it will breathe new vitality into Korea's biotech sector." Han expressed hope that the plant would "lead the leap of K-bio as a central pillar of the Songdo bio cluster."
Incheon Mayor Park said he was moved to see the facility completed as a fully operational production site, recalling that he had unveiled his vision for Incheon's biotech industry at the construction site in April when he was still a mayoral candidate. "I expect that the synergy between Incheon's research and development and talent-cultivation foundation and Lotte Biologics' global production capabilities will strengthen the competitiveness of the biotech industry," Park said.
Construction on Plant 1 at the Songdo Bio Campus began in March 2024. The facility, with a total floor area of approximately 99,558 square meters, received its occupancy permit in June. It is equipped with key facilities including a production building, utility building, welfare building and wastewater treatment plant, and has secured a biopharmaceutical production capacity of 120,000 liters through eight 15,000-liter stainless steel bioreactors. Following the occupancy permit, the company has been conducting equipment qualification assessments and validation procedures, and plans to begin full commercial production next year.
Lotte Biologics signed its first large-scale biopharmaceutical CMO contract for Plant 1 with a global pharmaceutical company on Tuesday, the day before the completion ceremony, demonstrating its commercial readiness. Unlike the industry norm of ramping up order activities after a plant is completed, the company employed a pre-order strategy — securing a major customer during the design and construction phases — to lock in the commercial production volume needed for early operation. Under the contract, the company will provide a one-stop service covering the full process from clinical active pharmaceutical ingredient production to finished drug products for the client's key products.
Lotte Biologics will now accelerate its dual-site strategy, linking the commercial production experience of its Syracuse Bio Campus in the United States with the large-scale manufacturing capacity of the Songdo campus. The company plans to apply the quality management expertise of its Syracuse facility — which has accumulated more than 62 regulatory approvals and recorded zero observations in a recent US Food and Drug Administration inspection — directly to Songdo, positioning itself to meet growing demand from global clients seeking supply chain diversification amid a global economic slowdown and uncertainties surrounding the US Biosecure Act.
silverpaper@heraldcorp.com